To include your compound in the COVID-19 Resource Center, submit it here.

TTP readout boosts Ablynx's shares

Ablynx N.V. (Euronext:ABLX) gained €3.18 (26%) to €15.50 on Monday after it said caplacizumab (ALX-0081/ALX-0681) met the primary endpoint in the Phase III HERCULES trial to treat acquired thrombotic

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE